FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216088338> ?p ?o ?g. }

• W3216088338 abstract "Background Antiretroviral drugs (ARV) reduce viral replication and can reduce mother‐to‐child transmission of HIV either by lowing plasma viral load in pregnant women or through post‐exposure prophylaxis in their newborns. In rich countries, highly active antiretroviral therapy (HAART) has reduced the vertical transmission rates to around 1‐2%, but HAART is not yet widely available in low and middle income countries. In these countries, various simpler and less costly antiretroviral regimens have been offered to pregnant women or to their newborn babies, or to both. Objectives To determine whether, and to what extent, antiretroviral regimens aimed at decreasing the risk of mother‐to‐child transmission of HIV infection achieve a clinically useful decrease in transmission risk, and what effect these interventions have on maternal and infant mortality and morbidity. Search methods We sought to identify all relevant studies regardless of language or publication status by searching the Cochrane HIV/AIDS Review Group Trials Register, The Cochrane Library, Medline, EMBASE and AIDSearch and relevant conference abstracts. We also contacted research organizations and experts in the field for unpublished and ongoing studies. The original review search strategy was updated in 2006. Selection criteria Randomised controlled trials of any antiretroviral regimen aimed at decreasing the risk of mother‐to‐child transmission of HIV infection compared with placebo or no treatment. Data collection and analysis Two authors independently selected relevant studies, extracted data and assessed trial quality. For the primary outcomes, we used survival analysis to estimate the probability of infants being infected with HIV (the observed proportion) at various specific time‐points and calculated efficacy at a specific time as the relative reduction in the proportion infected. Efficacy, at a specific time, is defined as the preventive fraction in the exposed group compared to the reference group, which is the relative reduction in the proportion infected: 1‐(Re/Rf). For those studies where efficacy and hence confidence intervals were not calculated, we calculated the approximate confidence intervals for the efficacy using recommended methods. For analysis of results that are not based on survival analyses we present the relative risk for each trial outcome based on the number randomised. No meta‐analysis was conducted as no trial assessed the identical drug regimens. Main results Eighteen trials including 14,398 participants conducted in 16 countries were eligible for inclusion in the review. The first trial began in April 1991 and assessed zidovudine (ZDV) versus placebo and since then, the type, dosage and duration of drugs to be compared has been modified in each subsequent trial. Antiretrovirals versus placebo In breastfeeding populations, three trials found that: ZDV given to mothers from 36 to 38 weeks gestation, during labour and for 7 days after delivery significantly reduced HIV infection at 4‐8 weeks (Efficacy 32.00%; 95% CI 0.64 to 63.36), 3 to 4 months (Efficacy 34.00%; 95% CI 6.56 to 61.44), 6 months (Efficacy 35.00%; 95% CI 9.52 to 60.48), 12 months (Efficacy 34.00%; 95% CI 8.52 to 59.48) and 18 months (Efficacy 30.00%; 95% CI 2.56 to 57.44). ZDV given to mothers from 36 weeks gestation and during labour significantly reduced HIV infection at 4 to 8 weeks (Efficacy 44.00%; 95% CI 8.72 to 79.28) and 3 to 4 months (Efficacy 37.00%; 95% CI 3.68 to 70.32) but not at birth. ZDV plus lamivudine (3TC) given to mothers from 36 weeks gestation, during labour and for 7 days after delivery and to babies for the first 7 days of life (PETRA 'regimen A') significantly reduced HIV infection (Efficacy 63.00%; 95% CI 41.44 to 84.56) and a combined endpoint of HIV infection or death (Efficacy 61.00%; 95% CI 41.40 to 80.60) at 4 to 8 weeks but these effects were not sustained at 18 months. ZDV plus 3TC given to mothers from the start of labour until 7 days after delivery and to babies for the first 7 days of life (PETRA 'regimen B') significantly reduced HIV infection (Efficacy 42.00%; 95% CI 12.60 to 71.40) and HIV infection or death at 4 to 8 weeks (Efficacy 36.00%; 95% CI 8.56 to 63.44) but the effects were not sustained at 18 months. ZDV plus 3TC given to mothers during labour only (PETRA 'regimen C') with no treatment to babies did not reduce the risk of HIV infection at either 4 to 8 weeks or 18 months. In non‐breastfeeding populations, three trials found that: ZDV given to mothers from 14 to 34 weeks gestation and during labour and to babies for the first 6 weeks of life significantly reduced HIV infection in babies at 18 months (Efficacy 66.00%; 95% CI 34.64 to 97.36). ZDV given to mothers from 36 weeks gestation and during labour with no treatment to babies ('Thai‐CDC regimen') significantly reduced HIV infection at 4 to 8 weeks (Efficacy 50.00%; 95% CI 12.76 to 87.24) but not at birth ZDV given to mothers from 38 weeks gestation and during labour with no treatment to babies did not influence HIV transmission at 6 months. Longer versus shorter regimens using the same antiretrovirals One trial in a breastfeeding population found that: ZDV given to mothers during labour and to their babies for the first 3 days of life compared with ZDV given to mothers from 36 weeks and during labour (similar to 'Thai‐CDC') resulted in HIV infection rates that were not significantly different at birth, 4‐8 weeks, 3 to 4 months, 6 months and 12 months. Three trials in non‐breastfeeding populations found that: ZDV given to mothers from 28 weeks gestation during labour and to infants for the first 3 days after birth compared with ZDV given to mothers from 35 weeks gestation through labour and to infants from birth to 6 weeks significantly reduced HIV infection rate at 6 months (Efficacy 45.00%; 95% CI 1.88 to 88.12) but compared with the same regimen ZDV given to mothers from 28 weeks gestation through labour and to infants from birth to 6 weeks did not result in a statistically significant difference in HIV infection at 6 months. ZDV given to mothers from 35 weeks gestation during labour and to infants for the first 3 days after birth was considered ineffective for reducing transmission rates and this regimen was discontinued. An antenatal/intrapartum course of ZDV used for a median of 76 days compared with an antenatal/intrapartum ZDV regimen used for a median 28 days with no treatment to babies in either group did not result in HIV infection rates that were significantly different at birth and at 3 to 4 months. In a programme where mothers were routinely receiving ZDV in the third trimester of pregnancy and babies were receiving one week of ZDV therapy, a single dose of nevirapine (NVP) given to mothers in labour and to their babies soon after birth compared with a single dose of NVP given to mothers only resulted in HIV infection rates that were not significantly different at birth and 6 months. However the reduction in risk of HIV infection or death at 6 months was marginally significant (Efficacy 45.00%; 95% CI ‐4.00 to 94.00). Antiretroviral regimens using different drugs and durations of treatment In breastfeeding populations, three trials found that: A single dose of NVP given to mothers at the onset of labour plus a single dose of NVP given to their babies immediately after birth ('HIVNET 012 regimen') compared with ZDV given to mothers during labour and to their babies for a week after birth resulted in lower HIV infection rates at 4‐8 weeks (Efficacy 41.00%; 95% CI 11.60 to 70.40), 3‐4 months (Efficacy 39.00%; 95% CI 11.56 to 66.44), 12 months (Efficacy 36.00%; 95% CI 8.56 to 63.44) and 18 months (Efficacy 39.00%; 95% CI 13.52 to 64.48). In addition, the NVP regimen significantly reduced the risk of HIV infection or death at 4‐8 weeks (Efficacy 42.00%; 95% CI 14.56 to 69.44), 3 to 4 months (Efficacy 40.00%; 95% CI 14.52 to 65.48), 12 months (Efficacy 32.00%; 95% CI 8.48 to 55.52) and 18 months (Efficacy 33.00%; 95% CI 9.48 to 56.52). The 'HIVNET 012 regimen' plus ZDV given to babies for 1 week after birth compared with the 'HIVNET 012 regimen' alone did not result in a statistically significant difference in HIV infection at 4 to 8 weeks. A single dose of NVP given to babies immediately after birth plus ZDV given to babies for 1 week after birth compared with a single dose of NVP given to babies only significantly reduced the HIV infection rate at 4 to 8 weeks (Efficacy 37.00%; 95% CI 3.68 to 70.32). Five trials in non‐breastfeeding populations found that: In a population in which mothers were receiving 'standard' ARV for HIV infection a single dose of NVP given to mothers in labour plus a single dose of NVP given to babies immediately after birth ('HIVNET 012 regimen') compared with placebo did not result in a statistically significant difference in HIV infection rates at birth and at 4 to 8 weeks. The 'Thai CDC regimen' compared with the 'HIVNET 012 regimen' did not result in a significant difference in HIV infection at 4 to 8 weeks. A single dose of NVP given to babies immediately after birth compared to ZDV given to babies for the first 6 weeks of life did not result in a significant difference in HIV infection rates at 4‐8 weeks and 3 to 4 months. ZDV plus 3TC given to mothers in labour and for a week after delivery and to their infants for a week after birth (similar to 'PETRA regimen B') compared with NVP given to mothers in labour and immediately after delivery plus a single dose of NVP to their babies immediately after birth (similar to 'HIVNET 012 regimen') did not result in a significant difference in the HIV infection rate at 4 to 8 weeks. An evaluation of various ARV drugs given to mothers from 34 to 36 weeks and during labour with the same drugs given to their babies for 6 weeks after birth: stavudine (d4T) versus ZDV, didanosine (ddI) versus ZDV and d4T plus ddI versus ZDV did not result in statistically important differences in HIV infection rates at birth, 4 to 8 weeks, 3 to 4 months and 6 months. Adverse effects The incidence of serious or life threatening events was not significantly different in any of the trials included in this review. Authors' conclusions Short courses of antiretroviral drugs are effective for reducing mother‐to‐child transmission of HIV and are not associated with any safety concerns in the short‐term. A combination of ZDV and 3TC given to mothers in the antenatal, intrapartum and postpartum periods and to babies for a week after delivery or a single dose of NVP given to mothers in labour and babies immediately after birth may be most effective. Where HIV infected women present late for delivery, post‐exposure prophylaxis with a single dose of NVP immediately after birth plus ZDV for the first 6 weeks of life is beneficial. The long term implications of the emergence of resistant mutations following the use of these regimens require further study" @default.
• W3216088338 created "2021-12-06" @default.
• W3216088338 creator A5080134746 @default.
• W3216088338 date "2007-01-24" @default.
• W3216088338 modified "2023-10-14" @default.
• W3216088338 title "Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection" @default.
• W3216088338 cites W1967503024 @default.
• W3216088338 cites W1968163372 @default.
• W3216088338 cites W1973529520 @default.
• W3216088338 cites W1977902784 @default.
• W3216088338 cites W1983878936 @default.
• W3216088338 cites W1987858510 @default.
• W3216088338 cites W1990105675 @default.
• W3216088338 cites W1991071311 @default.
• W3216088338 cites W1997498891 @default.
• W3216088338 cites W2005206478 @default.
• W3216088338 cites W2005264081 @default.
• W3216088338 cites W2006407786 @default.
• W3216088338 cites W2007982200 @default.
• W3216088338 cites W2009824933 @default.
• W3216088338 cites W2014366116 @default.
• W3216088338 cites W2017519401 @default.
• W3216088338 cites W2034781169 @default.
• W3216088338 cites W2037543597 @default.
• W3216088338 cites W2053211249 @default.
• W3216088338 cites W2054292852 @default.
• W3216088338 cites W2055369959 @default.
• W3216088338 cites W2056253108 @default.
• W3216088338 cites W2056477712 @default.
• W3216088338 cites W2058865932 @default.
• W3216088338 cites W2061912088 @default.
• W3216088338 cites W2071900258 @default.
• W3216088338 cites W2073831371 @default.
• W3216088338 cites W2081971477 @default.
• W3216088338 cites W2082956614 @default.
• W3216088338 cites W2083691996 @default.
• W3216088338 cites W2085560533 @default.
• W3216088338 cites W2086040638 @default.
• W3216088338 cites W2089596992 @default.
• W3216088338 cites W2101195795 @default.
• W3216088338 cites W2101943310 @default.
• W3216088338 cites W2102919880 @default.
• W3216088338 cites W2104853744 @default.
• W3216088338 cites W2104966707 @default.
• W3216088338 cites W2113906937 @default.
• W3216088338 cites W2114790957 @default.
• W3216088338 cites W2120255324 @default.
• W3216088338 cites W2125436283 @default.
• W3216088338 cites W2131832679 @default.
• W3216088338 cites W2133939403 @default.
• W3216088338 cites W2134507401 @default.
• W3216088338 cites W2137435663 @default.
• W3216088338 cites W2137498458 @default.
• W3216088338 cites W2138106725 @default.
• W3216088338 cites W2147072996 @default.
• W3216088338 cites W2148539641 @default.
• W3216088338 cites W2149132288 @default.
• W3216088338 cites W2154671568 @default.
• W3216088338 cites W2154959052 @default.
• W3216088338 cites W2155050390 @default.
• W3216088338 cites W2157380363 @default.
• W3216088338 cites W2169273126 @default.
• W3216088338 cites W2170947401 @default.
• W3216088338 cites W2172052919 @default.
• W3216088338 cites W2262700604 @default.
• W3216088338 cites W2275297659 @default.
• W3216088338 cites W2316970929 @default.
• W3216088338 cites W2318503132 @default.
• W3216088338 cites W2337158409 @default.
• W3216088338 cites W2339219218 @default.
• W3216088338 cites W2339995887 @default.
• W3216088338 cites W2527016823 @default.
• W3216088338 cites W4246418227 @default.
• W3216088338 doi "https://doi.org/10.1002/14651858.cd003510.pub2" @default.
• W3216088338 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17253490" @default.
• W3216088338 hasPublicationYear "2007" @default.
• W3216088338 type Work @default.
• W3216088338 sameAs 3216088338 @default.
• W3216088338 citedByCount "171" @default.
• W3216088338 countsByYear W32160883382012 @default.
• W3216088338 countsByYear W32160883382013 @default.
• W3216088338 countsByYear W32160883382014 @default.
• W3216088338 countsByYear W32160883382015 @default.
• W3216088338 countsByYear W32160883382016 @default.
• W3216088338 countsByYear W32160883382017 @default.
• W3216088338 countsByYear W32160883382018 @default.
• W3216088338 countsByYear W32160883382019 @default.
• W3216088338 countsByYear W32160883382020 @default.
• W3216088338 countsByYear W32160883382021 @default.
• W3216088338 countsByYear W32160883382022 @default.
• W3216088338 countsByYear W32160883382023 @default.
• W3216088338 crossrefType "reference-entry" @default.
• W3216088338 hasAuthorship W3216088338A5080134746 @default.
• W3216088338 hasConcept C159047783 @default.
• W3216088338 hasConcept C187212893 @default.
• W3216088338 hasConcept C3013748606 @default.
• W3216088338 hasConcept C41008148 @default.
• W3216088338 hasConcept C71924100 @default.
• W3216088338 hasConcept C761482 @default.
• W3216088338 hasConcept C76155785 @default.

• next